Advertisement

Small Vessel Vasculitides

  • Peter Lamprecht
  • Wolfgang L. Gross

Keywords

Systemic Vasculitis Churg Strauss Syndrome Mixed Cryoglobulinemia Small Vessel Vasculitis Rheumatoid Vasculitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Austin HA 3d, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314: 614–619PubMedGoogle Scholar
  2. Bergstein J, Leiser J, Andreoli SP (1998) Response of crescentic Henoch-Schoenlein purpura nephritis to corticosteroid and azathioprine therapy. Clin Nephrol 49: 9–14PubMedGoogle Scholar
  3. Birck R, Warnatz K, Lorenz HM, Choi M, Haubitz M, Grunke M, Peter HH, Kalden JR, Gobel U, Drexler JM, Hotta O, Nowack R, Van der Woude FJ (2003) 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: A six-month open-label trial to evaluate safety and efficacy. J Am Soc Nephrol 14, 440–447CrossRefPubMedGoogle Scholar
  4. Boumpas DT, Yamada H, Patronas NJ, Scott D, Klippel JH, Balow JE (1991) Pulse cyclo-phosphamide for severe neuropsychiatric lupus. Q J Med 81: 975–984PubMedGoogle Scholar
  5. Baumert E, Schlesier M, Wolff-Vorbeck G, Peter HH (1992) Alterations inlymphocyte subsets in variable immunodeficiency syndrome. Immun Infekt 20: 73–75PubMedGoogle Scholar
  6. Choi HK, Lamprecht P, Niles JL, Gross WL, Merkel PA (2000) Subacute bacterial endocarditis with positive C-ANCA and antiproteinase 3 antibodies. Arthritis Rheum 43: 226–231CrossRefPubMedGoogle Scholar
  7. Claudy A (1998) Pathogenesis of leukocytoclastic vasculitis. Eur J Dermatol 8: 75–79CrossRefPubMedGoogle Scholar
  8. Cockwell P, Brooks CJ, Adu D, Savage COS (1999) Interleukin-8: pathogenetic role in anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis. Kidney Int 55: 852–863CrossRefPubMedGoogle Scholar
  9. Csernok E, Lüdemann J, Gross WL, Bainton DF (1990) Ultrastructural localization of proteinase 3, the target antigen of anticytoplasmic antibodies circulating in Wegener’s granulomatosis. Am J Pathol 137: 1113–1120PubMedGoogle Scholar
  10. Csernok E, Trabandt A, Müller A, Wang GC, Moosig F, Paulsen J, Schnabel A, Gross WL (1999) Cytokine profiles in Wegner’s granulomatosis. Predominance of type 1 (Thl) in the granulomatous inflammation. Arthritis Rheum 42: 742–750PubMedGoogle Scholar
  11. Csernok E, Gross WL (2000) Primary vasculitides and vasculitis confined to the skin: clinical features and new pathogenic aspects. Arch Dermatol Res 292: 427–436.CrossRefPubMedGoogle Scholar
  12. Dammacco F, Sansonno D, Han JH, Shyamala V, Cornacchiulo V, Iacobelli AR, Lauletta G, Rizzi R (1994) Natural interferon-alpha versus its combination with 6-methyl-prednisolone in the therapy of type II mixed cryoglobulinemia: a long-term, randomized, controlled study. Blood 84: 3336–3343PubMedGoogle Scholar
  13. D’Amico G (1998) Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis. Kidney Int 54: 650–671CrossRefPubMedGoogle Scholar
  14. deGroot K, Reinhold-Keller E, Tatsis E, Paulsen J, Heller M, Nolle B, Gross WL (1996) Therapy for the maintenance of remission in sixty-five patients with generalized Wegener’s granulomatosis. Methotrexate versus trimethoprim/sulfamethoxazole. Arthritis Rheum 39:2052–2061PubMedGoogle Scholar
  15. deGroot K, Haubitz M, Haller H (2000) ANCA-assoziierte Vaskulitiden. Neue Konzepte und Strategien in der Therapie. Internist 41: 1112–1119PubMedGoogle Scholar
  16. Donada C, Crucitti A, Donadon V, Chemello L, Alberti A (1998) Interferon α and ribavirin combination therapy in patients with chronic hepatitis C and mixed cryoglobulinemia. Blood 92: 2983–2984PubMedGoogle Scholar
  17. Falk RJ, Jennette JC (1988) Anti-neutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 318: 1651–1657PubMedGoogle Scholar
  18. Falk RJ, Terrell RS, Charles LA, Jennette JC (1990) Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 87: 4115–4119PubMedGoogle Scholar
  19. Ferri C, Greco F, Longombardo G, Palla P, Moretti A, Marzo E, Fosella PV, Pasero G, Bombardieri (1991) Antibodies to hepatits C virus in patients with mixed cryoglobulinemia. Arthritis Rheum 34: 1606–1610PubMedGoogle Scholar
  20. Ferri C, Marzo E, Longombardo G, Lombardini F, La Civita L, Vanacore R, Liberati AM, Gerli R, Greco F, Moretti A (1993) Interferon-alpha in mixed cryoglobulinemia patients: a randomized, crossover-controlled trial. Blood 81: 1132–1136PubMedGoogle Scholar
  21. Fujioka A, Yamamoto T, Takasu H, Kawano K, Masuzawa M, Katsuoka K, Jinno S (1998) The analysis of mRNA expression of cytokines from skin lesions in Churg-Strauss syndrome. J Dermatol 25:171–177PubMedGoogle Scholar
  22. Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V (2000) TAP deficiency syndrome. Clin Exp Immunol 121: 173–178CrossRefPubMedGoogle Scholar
  23. Gause A, Inderrieden DC, Laas R, Arlt AC, Gross WL (2000) Common variable immunodeficiency (CVID) and inclusion body myositis. Immunobiology 202: 199–203PubMedGoogle Scholar
  24. Grimminger F, Hattar K, Papavassilis C, Temmesfeld B, Csernok E, Gross WL, Seeger W, Sibelius U (1996) Neutrophil activation by anti-proteinase 3 antibodies in Wegener’s granulomatosis: role of exogenous arachidonic acid and leukotrien B4 generation. J Exp Med 184: 1567–1572CrossRefPubMedGoogle Scholar
  25. Gross WL, Csernok E, Schmitt WH (1991) Antineutrophil cytoplasmic autoantibodies: immunobiolgical aspects. Klin Wochenschr 69: 558–566CrossRefPubMedGoogle Scholar
  26. Gross WL, Trabandt A, Reinhold-Keller E (2000) Diagnosis and evaluation of vasculitis. Rheumatology 39: 245–252CrossRefPubMedGoogle Scholar
  27. Gross WL (2003) Immunopathogenesis of vasculitis. In: Klippel JH, Dieppe PA (eds) Rheumatology. 3rd ed. Mosby, London, chapter 7.19, p. 1–8Google Scholar
  28. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, Lesavre P, Ludemann J, Rasmussen N, Sinico RA, Wiik A, van der Woude FJ (1998) Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 53: 743–753CrossRefPubMedGoogle Scholar
  29. Hautmann G, Campanile G, Lotti TM (1999) The many faces of cutaneous vasculitis. Clin Dermatol 17: 515–531CrossRefPubMedGoogle Scholar
  30. Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–498PubMedGoogle Scholar
  31. Hunder GG, Arend WP, Bloch DA, Calabrese LH, Fauci AS, Fries JF, Leavitt RY, Lie JT, Lightfoot RW Jr, Masi AT, McShane DJ, Michel BA, Mills JA, Stevens MB, Wallace SL, Zvaifler NJ (19990) The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum 33: 1065–1067Google Scholar
  32. Jayne DR, Chapel H, Adu D, Misbah S, O’Donoghue D, Scott D, Lockwood CM (2000) Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 93: 433–439PubMedGoogle Scholar
  33. Jayne D, Rasmussen N, Andrassy K, Bacon PA, Cohen Tervaert JW, Dadoniene J, Ekstrand A, Gaskin G, Gregorni G, deGroot K, Gross WL, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C, for the European Vasculitis Study Group (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil autoantibodies. N Engl J Med 349: 36–44CrossRefPubMedGoogle Scholar
  34. Jenne DE, Tschopp J, Lüdemann J, Utech B, Gross WL (1990) Wegener’s autoantigen decoded. Nature 346: 520.CrossRefGoogle Scholar
  35. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, Hagen EC, Hoffman GS, Hunder GG, Kallenberg CG, McCluskey RT, Sinico A, Rees AJ, van Es LA, Waldherr R, Wiik A (1994) Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 37: 187–192PubMedGoogle Scholar
  36. Jennette JC, Falk R. (1997) Small-vessel vasculitis. N Engl J Med 337: 1512–1523CrossRefPubMedGoogle Scholar
  37. Kallenberg CG, Cohen Tervaert JW (2000) New treatments of ANCA-associated vasculitis. Sarcoidosis Vasc Diffuse Lung Dis 17: 125–129PubMedGoogle Scholar
  38. Kiene M, Csernok E, Müller A, Metzler C, Trabandt A, Gross WL (2001) Elevated IL-4 and IL-13 production by T-cell lines in Churg-Strauss syndrome. Arthritis Rheum 44:469–473CrossRefPubMedGoogle Scholar
  39. Kocher M, Edberg JC, Fleit HB, Kimberly RP (1998) Antineutrophil cytoplasm antibodies preferentially engage Fc gammaRIIIb on human neutrophils. J Immunol 161: 6909–6914PubMedGoogle Scholar
  40. Komocsi A, Lamprecht P, Csernok E, Müller A, Holl-Ulrich K, Seitzer U, Moosig F, Schnabel A, Gross WL (2002) Peripheral blood and granuloma CD4+CD28 T-cells are a major source of IFNγ and TNF-α in Wegener’s granulomatosis. Am J Pathol 160: 1717–1724PubMedGoogle Scholar
  41. Langford CA, Talar-Williams C, Sneller MC. Use of methotrexate and glucocorticoids in the treatment of Wegener’s granulomatosis. Long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 43: 1836–1840Google Scholar
  42. Lamprecht P, Gause A, Gross WL (1999). Cryoglobulinemic vasculitis. Arthritis Rheum 42:2507–2516CrossRefPubMedGoogle Scholar
  43. Lamprecht P, Trabandt A, Gross WL (2000) Clinical and immunological aspects of Wegener’s granulomatosis (WG) and other syndromes resembling WG. Isr Med Assoc J 2: 621–626PubMedGoogle Scholar
  44. Lamprecht P, Voswinkel J, Lilienthal T, Nölle B, Heller M, Gross WL, Gause A (2002) Effectiveness of TNF-α blockade with infliximab in refractory Wegener’s granulomatosis. Rheumatology 41: 1303–1307PubMedGoogle Scholar
  45. Lamprecht P, Erdmann A, Müller A, Csernok E, Reinhold-Keller E, Holl-Ulrich K, Feller AC, Brühl H, Gross WL (2003a) Heterogeneity of CD4+ and CD8+ memory T cells in localized and generalized Wegener’s granulomatosis. Arthritis Res Ther 5: R25–R31CrossRefPubMedGoogle Scholar
  46. Lamprecht P, Brühl H, Erdmann A, Holl-Ulrich K, Csernok E, Seitzer U, Mack M, Feller AC, Reinhold-Keller E, Gross WL, Müller A (2003b) Differences in CCR5 expression on peripheral blood CD4+CD28 T-cells and in granulomatous lesions between localized and generalized Wegener’s granulomatosis. Clin Immunol 108: 1–7CrossRefPubMedGoogle Scholar
  47. Lamprecht P, Gross WL (2004) Wegener’s granulomatosis. Herz 29: 47–56CrossRefPubMedGoogle Scholar
  48. Lamprecht P, Müller A, Gross WL (2004a) CD28 T-cells display features of effector memory T-cells in Wegener’s granulomatosis. Kidney Int 65:1113.CrossRefPubMedGoogle Scholar
  49. Lamprecht P, Moosig F, Adam-Klages S, Mrowietz U, Csernok E, Kirrstetter M, Ahmadi-Simab K, Schröder JO, Gross WL (2004b) Small vessel vasculitis and relapsing panniculitis in tumor necrosis factor receptor-associated periodic syndrome (TRAPS). Ann Rheum Dis in pressGoogle Scholar
  50. Lanham JG, Elkon KB, Pusey CD, Hughes GR (1984) Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 63: 65–81PubMedGoogle Scholar
  51. Ludviksson BJ, Sneller MC, Chua KS, Talar-Williams C, Langford CA, Ehrhardt RO, Fauci AS, Strober W (1998) Active Wegener’s granulomatosis is associated with HLA-DR+CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J Immunol 160: 3602–3609PubMedGoogle Scholar
  52. Metzler C, Tatsis E, Gause A, Gross WL (2000) Long-term treatment of Churg-Strauss syndrome with interferon-α. Arthritis Rheum 43(Suppl): S369Google Scholar
  53. Metzler C, Fink C, Lamprecht P, Gross WL, Reinhold-Keller E (2004) Maintenance of remission with leflunomid in Wegener’s granulomatosis. Rheumatology 43: 315–320CrossRefPubMedGoogle Scholar
  54. Moins-Teisserenc HT, Gadola SD, Cella M, Dunbar PR, Exley A, Blake N, Baycal C, Lambert J, Bigliardi P, Willemsen M, Jones M, Buechner S, Colonna M, Gross WL, Cerundolo V (1999) Association of a syndrome resembling Wegener’s granulomatosis with low surface expression of HLA class-I molecules. Lancet 354: 1598–1603CrossRefPubMedGoogle Scholar
  55. Moosig F, Csernok E, Reinhold-Keller E, Schmitt W, Gross WL (1998) Elevated procalcitonin levels in active Wegener’s granulomatosis. J Rheumatol 25: 1531–1533PubMedGoogle Scholar
  56. Müller A., Trabandt A, Glöckner-Hofmann K, Seitzer U, Csernok E, Schönermarck U, Feller AC, Gross WL (2000) Localized Wegener’s granulomatosis: predominance of CD26 and IFNγ expression. J Path 192: 113–120CrossRefPubMedGoogle Scholar
  57. Pendergraft WE, Preston GA, Shah R, Tropsha A, Carter CW, Jennette JC, Falk RJ (2004) Autoimmunity is triggered by cPR3(105-201), a protein complementary to human autoantigen proteinase 3. Nature Med 10: 72–79CrossRefPubMedGoogle Scholar
  58. Porges AJ, Redecha PB, Kimberly WT, Csernok E, Gross WL, Kimberly RP (1994) Anti-neutrophil cytoplasmic antibodies engage and activate human neutrophils via Fc gamma RIIa. J Immunol 153: 1271–1280PubMedGoogle Scholar
  59. Powell FC, Schroeter AL, Su WPD, Perry HO (1985) Pyoderma gangrenosum: A review of 86 patients. Q J Med 55: 173–82PubMedGoogle Scholar
  60. Radford DJ, Luu NT, Hewins P, Nash GB, Savage CO (2000) Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum 44: 2851–2861CrossRefGoogle Scholar
  61. Rao JK, Allen NB, Pincus T (1998) Limitations of the 1990 American College of Rheuamtology classification criteria in the diagnosis of vasculitis. Ann Intern Med 129: 345–352PubMedGoogle Scholar
  62. Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A, Duncker G, Gross WL (1994) Influence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener’s granulomatosis. Arthritis Rheum 37: 919–924PubMedGoogle Scholar
  63. Reinhold-Keller E, Beuge N, Latza U, de Groot K, Rudert H, Nolle B, Heller M, Gross WL (2000) An interdisciplinary approach to the care of patients with Wegener’s granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 43: 1021–1032CrossRefPubMedGoogle Scholar
  64. Sais G, Vidaller A, Servitje O, Jucgla A, Peyri J (1996) Leukocytoclastic vasculitis and common variable immunodeficiency: successful treatment with intravenous immune globulin. J Allergy Clin Immunol 98: 232–233.PubMedGoogle Scholar
  65. Sansonno D, Lauletta G, Nisi L, Gatti P, Pesola F, Pansini N, Dammacco F (2003) Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complex in type II mixed cryoglobulinemia. Clin Exp Immunol 133: 275–282CrossRefPubMedGoogle Scholar
  66. Savage COS, Harper L, Adu D (1997) Primary systemic vasculitis. Lancet 349: 553–558CrossRefPubMedGoogle Scholar
  67. Schmitt WH, Gross WL (1998) Vasculitis in the seriously ill patient: diagnostic approaches and therapeutic options in ANCA-associated vasculitis. Kidney Int Suppl 64: S39–44PubMedGoogle Scholar
  68. Schmitt WH, Hagen EC, Neumann I, Nowack R, Flores-Suarez LF, Van der Woude FJ, for the European Vasculitis Group (2004) Treatment of refractory Wegener’s granulomatosis with antithymocyte globulin (ATG): An open study in 15 patients. Kidney Int 65: 1440–1448PubMedGoogle Scholar
  69. Schönermarck U, Lamprecht P, Csernok E, Gross WL (2000) Prevalence and spectrum of rheumatic diseases associated with PR3-ANCA and MPO-ANCA. Rheumatology in press.Google Scholar
  70. Schur PH (1993) Clinical features of SLE. In: Kelley WN, Harris ED Jr, Ruddy S, Sledge CB (eds) Textbook of Rheumatology, Volume 2. WB Saunders Company, Philadelphia London Toronto Montreal Sydney Tokyo, pp 1017–1042Google Scholar
  71. Scott DG, Bacon PA (1984) Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis. Am J Med 76: 377–384PubMedGoogle Scholar
  72. Sneller MC (2002) Granuloma formation, implications for the pathogensis of vasculitis. Cleveland Clin J Med 69(Suppl. 2): SII-40–SII-43Google Scholar
  73. Stegeman CA, Cohen Tervaert JW, de Jong PE, Kallenberg CGM (1996) Trimethoprim-sulfmethoxazole (Co-trimoxazole) for the prevention of relapses in Wegener’s granulomatosis. N Engl J Med 335: 16–20CrossRefPubMedGoogle Scholar
  74. Stone JH for the WGET investigators (2000) Etanercept in Wegner’s granulomatosis (WG): Design of a randomized, multi-center trial. Clin Exp Immunol 120(Suppl 1): 72Google Scholar
  75. Tatsis E, Schnabel A, Gross WL (1998) Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann Intern Med 129: 370–374PubMedGoogle Scholar
  76. Tsukadaira A, Okubo Y, Kitano K, Horie S, Momose T, Takashi S, Suzuki J, Isobe M, Sekiguchi M (1999) Eosinophil active cytokines and surface analysis of eosinophils in Churg-Strauss syndrome. Allergy Asthma Proc 20: 39–44PubMedGoogle Scholar
  77. Voswinkel J, Müller A, Lamprecht P, Gause A, Gross WL (2002) Does ANCA formation result from an antigen-triggered immune response in Wegener’s endonasal inflamed tissue? (Abstract) Cleveland Clin. J. Med. 69-Supl.2: SII–159.Google Scholar
  78. Wei G, Yano S, Kuroiwa T, Hiromura K, Maezawa A (1997) Hepatitis C virus (HCV)-induced IgG-IgM rheumatoid factor (RF) complex may be the main causal factor for cold-dependent activation of complement in patients with rheumatic disease. Clin Exp Immunol 107:83–88.CrossRefPubMedGoogle Scholar
  79. Winek J, Müller A, Csernok E, Gross WL, Lamprecht P (2004) Frequency of proteinase 3 (PR3)-specific autoreactive T-cells determined by cytokine flow cytometry in Wegener’s granulomatosis. J Autoimmun 22: 79–85CrossRefPubMedGoogle Scholar
  80. Xiao H, Heeringa P, Hu P, Liu Z, Zhao M, Aratani Y, Maeda N, Falk RJ, Jennette JC (2002) Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 110: 955–963CrossRefPubMedGoogle Scholar
  81. Yang JJ, Preston GA, Alcorta DA, Waga I, Munger WE, Hogan SL, Sekura SB, Phillips BD, Thomas RP, Jennette JC, Falk RJ (2002) Expression profile of leukocyte genes activated by anti-neutrophil cytoplasmic autoantibodies (ANCA). Kidney Int 62: 1638–1649.CrossRefPubMedGoogle Scholar
  82. Zaja F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M Fanin R, Ferraccioli G (2003). Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 101: 3827–3834CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2005

Authors and Affiliations

  • Peter Lamprecht
  • Wolfgang L. Gross

There are no affiliations available

Personalised recommendations